A BILL 
To direct the Secretary of Health and Human Services to 
award contracts, grants, and cooperative agreements to 
expand and enhance manufacturing capacity of vaccines 
and vaccine candidates to prevent the spread of SARS– 
CoV–2 and COVID–19. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. VACCINE MANUFACTURING AND ADMINISTRA-
3
TION CAPACITY. 
4
(a) ENHANCING MANUFACTURING CAPACITY.— 
5
(1) IN GENERAL.—The Secretary of Health and 
6
Human Services (in this section referred to as the 
7
02:29 Jun 27, 2020
H7104
ctelli on DSK30NT082PROD with BILLS
2 
•HR 7104 IH
‘‘Secretary’’) acting through the Director of the Bio-
1
medical Advanced Research and Development Au-
2
thority shall, as appropriate, award contracts, 
3
grants, and cooperative agreements, and enter into 
4
other transactions, to expand and enhance manufac-
5
turing capacity of vaccines and vaccine candidates to 
6
prevent the spread of SARS–CoV–2 and COVID–19. 
7
(2) AUTHORIZATION OF APPROPRIATIONS.—To 
8
carry out this subsection, there are authorized to be 
9
appropriated such sums as may be necessary for fis-
10
cal years 2020 through 2024, to remain available 
11
until expended. 
12
(b) REPORT ON VACCINE MANUFACTURING AND AD-
13
MINISTRATION CAPACITY.— 
14
(1) IN GENERAL.—Not later than December 31, 
15
2020, the Secretary shall submit to the Committee 
16
on Energy and Commerce of the House of Rep-
17
resentatives and the Committee on Health, Edu-
18
cation, Labor and Pensions of the Senate a report 
19
detailing— 
20
(A) an assessment of the estimated supply 
21
of vaccines and ancillary medical products re-
22
lated to vaccine administration necessary to 
23
control and stop the spread of SARS–CoV–2 
24
04:14 Jun 24, 2020
H7104
ctelli on DSK30NT082PROD with BILLS
3 
•HR 7104 IH
and COVID–19, domestically and internation-
1
ally; 
2
(B) an assessment of current and future 
3
domestic manufacturing capacity for vaccines or 
4
vaccine candidates to control or stop the spread 
5
of SARS–CoV–2 and COVID–19, vaccine can-
6
didates, and ancillary products related to the 
7
administration of such vaccines, including iden-
8
tification of any gaps in manufacturing capac-
9
ity; 
10
(C) activities conducted to expand and en-
11
hance manufacturing capacity for vaccines, vac-
12
cine candidates, and ancillary medical products 
13
to levels sufficient to control and stop the 
14
spread of SARS–CoV–2 and COVID–19, do-
15
mestically and internationally, including a list 
16
and explanation of all contracts, grants, and co-
17
operative agreements awarded, and other trans-
18
actions entered into, for purposes of such ex-
19
pansion and enhancement and how such activi-
20
ties will help to meet future domestic manufac-
21
turing capacity needs; 
22
(D) a plan for the ongoing support of en-
23
hanced manufacturing capacity for vaccines, 
24
vaccine candidates, and ancillary medical prod-
25
04:14 Jun 24, 2020
H7104
ctelli on DSK30NT082PROD with BILLS
4 
•HR 7104 IH
ucts sufficient to control and stop the spread of 
1
SARS–CoV–2 and COVID–19, domestically 
2
and internationally; and 
3
(E) a plan to support the administration of 
4
vaccines approved or authorized by the Food 
5
and Drug Administration to control and stop 
6
the spread of SARS–CoV–2 and COVID–19, 
7
domestically and internationally, including Fed-
8
eral workforce enhancements necessary to ad-
9
minister such vaccines. 
10
(2) ANCILLARY MEDICAL PRODUCTS.—For pur-
11
poses of this subsection, ‘‘ancillary medical prod-
12
ucts’’ includes— 
13
(A) vials; 
14
(B) bandages; 
15
(C) alcohol swabs; 
16
(D) syringes; 
17
(E) needles; 
18
(F) gloves and other personal protective 
19
equipment; and 
20
(G) other medical products the Secretary 
21
determines necessary for the administration of 
22
vaccines. 
23
Æ 
04:14 Jun 24, 2020
H7104
ctelli on DSK30NT082PROD with BILLS
